TCAP-1 has shown encouraging results in pre-clinical neurologic testing in anxiety and depression.
TCAP-1 (teneurin C-terminal associated peptides (TCAP), a family of peptides that play a major role in energy regulation and are found in all animals.) is a promising treatment for anxiety and depression as it appears to alleviate high stress response-related behaviors. Mechanistic studies found that it is because TCAP-1 ablates the effect of the stress-inducing hormone, CRF, thus resulting in the significant decline of anxious nature. Our current work aims to actively pursue therapies that harness the stress-diminishing capabilities of TCAP-1 in order to increase stress-response. By doing so, we can help reduce the manifestations of anxiety on a day-to-day basis.
Over the past few years, we have established the scientific foundation for our lead molecule to achieve this potential. A better understanding of PT00114’s mechanism of action has helped us with the interpretation and design of preclinical experiments. Our lead compound is potentially a ‘first-in-class’ drug.
Our studies have shown evidence that PT00114 is a strong regulator of cellular metabolism, including neuronal cells. Because this mechanism is similar across different animal species and humans, we believe that our experimental observations can form the basis for our molecule to work by profoundly improving neuronal health. Such a regulation of energy metabolism in the brain formed the impetus for us to pursue, depression, anxiety and various stress-related disorders as a first set of potential indications.